These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Dyskinesia caused by L-DOPA]. Derkinderen P; Vidailhet M Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668 [TBL] [Abstract][Full Text] [Related]
5. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease]. Maurel F; Lilliu H; Le Pen C Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770 [TBL] [Abstract][Full Text] [Related]
6. [Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism]. Arlazoroff A; Flechtir S; Goldexberg E; Bleicher Z; Barber Y Harefuah; 1985 Mar; 108(5):227-9. PubMed ID: 4007677 [No Abstract] [Full Text] [Related]
7. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease. Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399 [No Abstract] [Full Text] [Related]
8. [Physiopathology of the dyskinesias induced by L-dopa]. Grandas F; López-Ariztegui N Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682 [TBL] [Abstract][Full Text] [Related]
9. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Rascol O Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400 [No Abstract] [Full Text] [Related]
10. Ocular dyskinesias in patients with Parkinson's disease treated with levodopa. Shimizu N; Cohen B; Bala SP; Mendoza M; Yahr MD Ann Neurol; 1977 Feb; 1(2):167-71. PubMed ID: 889300 [No Abstract] [Full Text] [Related]
11. ["Beginning and end of dose" dyskinesias caused by L-DOPA]. Lhermitte F; Agid Y; Signoret JL; Studler JM Rev Neurol (Paris); 1977 May; 133(5):297-308. PubMed ID: 897439 [TBL] [Abstract][Full Text] [Related]
12. [Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa]. Haas JA; Lakke JP Ned Tijdschr Geneeskd; 1982 Apr; 126(16):701-5. PubMed ID: 7088202 [No Abstract] [Full Text] [Related]
13. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease. Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256 [TBL] [Abstract][Full Text] [Related]
14. [Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa]. Perret J; Feuerstein C; Pellat J; Serre F; Gavend M; Tanche M Rev Neurol (Paris); 1977 Nov; 133(11):627-36. PubMed ID: 601391 [TBL] [Abstract][Full Text] [Related]
15. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy. Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479 [TBL] [Abstract][Full Text] [Related]
16. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease. Rice JE; Antic R; Thompson PD Mov Disord; 2002 May; 17(3):524-7. PubMed ID: 12112201 [TBL] [Abstract][Full Text] [Related]
17. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients]. Vaamonde J; Ibáñez R; Gudín M; Hernández A Neurologia; 2003 Apr; 18(3):162-5. PubMed ID: 12677484 [TBL] [Abstract][Full Text] [Related]
18. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808 [TBL] [Abstract][Full Text] [Related]
19. Improvement of L-dopa induced dyskinesia and of on-off phenomenon by bromocriptine. Ludin HP Acta Neurol Belg; 1980; 80(1):5-9. PubMed ID: 7361542 [No Abstract] [Full Text] [Related]
20. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias. Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945 [No Abstract] [Full Text] [Related] [Next] [New Search]